Newer Antiepileptic Drugs: Possible Uses in the Treatment of Neuropathic Pain and Migraine

Clinical Therapeutics

Volumn 25, Issue 10, 2003, Pages 2506-2538

  Pappagallo, Marco ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Anticonvulsant drugs; Antiepileptic drugs; Migraine headache; Neuropathic pain; Novel analgesics; Pain treatment

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; FLUPHENAZINE; GABAPENTIN; LAMOTRIGINE; NORTRIPTYLINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ANOREXIA; ATAXIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DIABETIC NEUROPATHY; DIPLOPIA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EPILEPSY; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; HYPONATREMIA; INFECTION; LANGUAGE DISABILITY; MEMORY DISORDER; MIGRAINE; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; NEUROPATHIC PAIN; NOCICEPTION; NYSTAGMUS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; POSTHERPETIC NEURALGIA; PSYCHOMOTOR DISORDER; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SPEECH DISORDER; TREMOR; VERTIGO; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0242509095     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80314-4     Document Type: Article

References (144)

1. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol. 2002;22:27-39.
2. Bolay H, Moskowitz MA. Mechanisms of pain modulation in chronic syndromes. Neurology. 2002;59(Suppl 2):S2-S7.
3. Chung JM, Chung K. Importance of hyperexcitability of DRG neurons in neuropathic pain. Pain Pract. 2002;2:87-97.
4. Baron R. Peripheral neuropathic pain: From mechanisms to symptoms. Clin J Pain. 2000;16(Suppl 2):S12-S20.
5. Costigan M, Woolf CJ. Pain: Molecular mechanisms. J Pain. 2000;1(Suppl):35-44.
6. Cutrer FM, Limmroth V, Waeber C, et al. New targets for antimigraine drug development. In: Goadsby PJ, Silberstein SD, eds. Blue Books of Practical Neurology. Vol 17. Boston, Mass: Butterworth-Heinemann; 1997:59-72.
7. Cutrer FM. Antiepileptic drugs: How they work in headache. Headache. 2001;41(Suppl 1):S3-S10.
8. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain. 2003;19:59-68.
9. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand. 2000;101:359-371.
10. Wallace M. Calcium and sodium channel antagonists for the treatment of pain. Clin J Pain. 2000;16(Suppl 2):S80-S85.
11. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA. 1998;280:1837-1842.
12. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA. 1998;280:1831-1836.
13. Silberstein SD, Goadsby PJ. Migraine: Preventive treatment. Cephalalgia. 2002;22: 491-512.
14. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology. 2002;59(Suppl 2):S14-S17.
15. Benedetti C, Dickerson ED, Nichols LL. Medical education: A barrier to pain therapy and palliative care. J Pain Symptom Manage. 2001;21:360-362.
16. Stedman's Medical Dictionary. 22nd ed. Baltimore, Md: Williams & Wilkins; 1972.
17. Merskey H, Bogduk N. International Association for the Study of Pain (IASP). Classification of Chronic Pain. 2nd ed. Seattle, Wash: IASP Press; 1994:210.
18. Dworkin RH. An overview of neuropathic pain: Syndromes, symptoms, signs, and several mechanisms. Clin J Pain. 2002;18:343-349.
19. Wasner G, Schattschneider J, Binder A, Baron R. Complex regional pain syndrome - diagnostic, mechanisms, CNS involvement and therapy. Spinal Cord. 2003;41:61-75.
20. Burchiel KJ. Trigeminal neuropathic pain. Acta Neurochir Suppl. 1993;58:145-149.
21. Serpell MG, for the Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: A randomised, double-blind, placebo-controlled trial. Pain. 2002;99: 557-566.
22. Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin J Pain. 2000;16(Suppl 2):S101-S105.
23. Cunha JM, Cunha FQ, Poole S, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J Pharmacol. 2000;130: 1418-1424.
24. Kocoglu H, Pirbudak L, Pence S, Balat O. Cancer pain, pathophysiology, characteristics and syndromes. Eur J Gynaecol Oncol. 2002;23:527-532.
25. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(Suppl 7):1-96.
26. Lipton RB, Newman LC. Epidemiology, impact, and comorbidities of migraine headache in the United States. Neurology. 2003;60(Suppl 2):S3-S8.
27. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - a prevalence study. J Clin Epidemiol. 1991;44:1147-1157.
28. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology. 1994;44(Suppl 4):S17-S23.
29. Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol. 1994;34(Suppl 2): 6-11.
30. Lipton RB, Baggish JS, Stewart WF, et al. Efficacy and safety of acetaminophen in the treatment of migraine: Results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med. 2000;160:3486-3492.
31. Codispoti JR, Prior MJ, Fu M, et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache. 2001;41:665-679.
32. Diener HC, Jansen JP, Reches A, et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: A multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol. 2002;47:99-107.
33. Rapoport AM. Pharmacological prevention of migraine. Clin Neurosci. 1998;5:55-59.
34. Silberstein SD, Freitag FG. Preventive treatment of migraine. Neurology. 2003;60 (Suppl 2):S38-S44.
35. Mathew NT. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin. 1997;15:167-186.
36. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache. 2003;43:171-178.
37. Edmeads J. Communication issues in migraine diagnosis. Can J Neurol Sci. 2002; 29(Suppl 2):S8-S10.
38. Doubell TP, Mannion RJ, Woolf CJ. The dorsal horn: State-dependent sensory processing, plasticity and the generation of pain. In: Wall PD, Melzack R, eds. Textbook of Pain. 4th ed. London: Churchill Livingstone; 1999:165-182.
39. Craig AD, Dostrovsky JO. Medulla to thalamus. In: Wall PD, Melzack R, eds. Textbook of Pain. 4th ed. London, Churchill Livingstone; 1999:183-214.
40. Ebersberger A. Pathophysiology of migraine: Models to explain the generation of migraine headache [in German]. Anaesthesist. 2002;51:661-667.
41. Rome HP, Rome JD. Limbically augmented pain syndrome - LAPS. Pain Med. 2000;1:9-21.
42. Mamet J, Baron A, Lazdunski M, Voilley N. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J Neurosci. 2002;22:10662-10670.
43. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: Behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids. 2002;121:173-190.
44. Decker MW, Meyer MD, Sullivan JP. The therapeutic potential of nicotinic acetylcholine receptor antagonists for pain control. Expert Opin Investig Drugs. 2001;10: 1819-1830.
45. Waxman SG. Acquired channelopathies in nerve injury and MS. Neurology. 2001;56: 1621-1627.
46. Lidbeck J. Central hyperexcitability in chronic musculoskeletal pain: A conceptual breakthrough with multiple clinical implications. Pain Res Manag. 2002;7:81-92.
47. Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain. 2000;4:5-15.
48. Noda Y, Mori A, Packer L. Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus. Res Commun Mol Pathol Pharmacol. 1999;105:23-33.
49. Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol. 2000;15(Suppl 3):28-35.
50. Ptacek LJ. The place of migraine as a channelopathy. Curr Opin Neurol. 1998;11:217-226.
51. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech. 2001;53:167-178.
52. Buzzi MG. Trigeminal pain pathway: Peripheral and central activation as experimental models of migraine. Funct Neurol. 2001;16(Suppl 4):77-81.
53. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headache. Nature. 1996;384:560-564.
54. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience. 1992;48:187-203.
55. Goadsby PJ. New aspects of the pathophysiology of migraine and cluster headache. In: Max M, ed. Pain 1999 - An Updated Review. Seattle, Wash: IASP Press; 1999:181-191.
56. Thomsen LL, Olesen J. Nitric oxide theory of migraine. Clin Neurosci. 1998;5:28-33.
57. Finnerup NB, Gottrup H, Jensen TS. Anticonvulsants in central pain. Expert Opin Pharmacother. 2002;3:1411-1420.
58. Engelborghs S, D'Hooge R, De Deyn PP. Pathophysiology of epilepsy. Acta Neurol Belg. 2000;100:201-213.
59. Chaplan SR, Guo HQ, Lee DH, et al. Neuronal hyperpolarization-activated pacemaker channels drive neuropathic pain. J Neurosci. 2003;23:1169-1178.
60. Sakas DE, Whittaker KW, Whitwell HL, Singounas EG. Syndromes of posttraumatic neurological deterioration in children with no focal lesions revealed by cerebral imaging: Evidence for a trigeminovascular pathophysiology. Neurosurgery. 1997;41:661-667.
61. Ottman R, Lipton RB. Comorbidity of migraine and epilepsy. Neurology. 1994;44: 2105-2110.
62. Terwindt GM, Ophoff RA, Haan J, et al, for the Dutch Migraine Genetics Research Group. Migraine, ataxia and epilepsy: A challenging spectrum of genetically determined calcium channelopathies. Eur J Hum Genet. 1998;6:297-307.
63. Eggers AE. New neural theory of migraine. Med Hypotheses. 2001;56:360-363.
64. Giroud M, Couillault G, Arnould S, et al. Epilepsy with rolandic paroxysms and migraine, a non-fortuitous association. Results of a controlled study [in French]. Pediatrie. 1989;44:659-664.
65. Backonja MM. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain. 2000;16(Suppl 2):S67-S72.
66. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs. 2000;60:1029-1052.
67. Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res. 1998;30:153-158.
68. Blom S. Trigeminal neuralgia: Its treatment with a new anticonvulsant drug. Lancet. 1962;1:839-840.
69. Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbazepine (Tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry. 1966;29:265-267.
70. Nicol CF. A four year double-blind study of Tegretol in facial pain. Headache. 1969;9:54-57.
71. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): Double blind crossover trial. Diabetologia. 1969;5:215-218.
72. Gomez-Perez FJ, Choza R, Rios JM, et al. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res. 1996;27:525-529.
73. Leijon G, Boivie J. Central post-stroke pain - a controlled trial of amitriptyline and carbamazepine. Pain. 1989;36:27-36.
74. Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use and side effects. Arch Neurol. 1968;19:129-136.
75. Saudek CD, Werns S, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther. 1977;22:196-199.
76. Chadda VS, Mathur MS. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India. 1978;26:403-406.
77. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain. 1999;83:389-400.
78. Jensen R, Brinck T, Olesen J. Sodium valproate has prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study. Neurology. 1994;44:647-651.
79. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: A double-blind study versus placebo. Cephalalgia. 1992;12:81-84.
80. Klapper JA. An open label crossover comparison of divalproex sodium and propranolol HCl in the prevention of migraine headaches. Headache Q. 1994;5:50-53.
81. Klapper JA. Divalproex sodium in migraine prophylaxis: A dose-controlled study. Cephalalgia. 1997;17:103-108.
82. Limmroth V, Katsarava Z, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002;59:1011-1014.
83. Rice AS, Maton S, for the Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain. 2001; 94:215-224.
84. Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: A placebo-controlled trial. Neurology. 2003;60:1508-1514.
85. Simpson DM, Olney R, McArthur JC, et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology. 2000;54:2115-2119.
86. Vestergaard K, Andersen G, Gottrup H, et al. Lamotrigine for central poststroke pain: A randomized controlled trial. Neurology. 2001;56:184-190.
87. McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: A randomised, double-blind, placebo controlled trial. Pain. 1999;83:105-107.
88. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study. Neurology. 2001;57:505-509.
89. Vinik A, Hewitt D, Xiang J, et al. Topiramate in the treatment of painful diabetic neuropathy: Results from a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 2003;60(Suppl 1):A154-A155. Abstract.
90. Edwards KR, Glanz MJ, Button J, et al. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Neurology. 2000;54:A81. Abstract.
91. Gilron I, Booher SL, Rowan JS, Max MB. Topiramate in trigeminal neuralgia: A randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol. 2001;24:109-112.
92. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:119-128.
93. Storey JR, Potter DL, Hart DE, Calder CS. A double blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. Neurology. 2000;54:A267-A268. Abstract.
94. Edwards KR, Glanz MJ, Shea P, et al. A double blind, randomized trial of topiramate versus placebo in the prophylactic treatment of migraine headache with and without aura. Cephalalgia. 2000;20:S16. Abstract.
95. Mathew NT, Dodick DW, Schmitt J, et al. Topiramate in migraine prevention (MIGR-001): Effect on migraine frequency. Neurology. 2003;60(Suppl 1):A336. Abstract S42.001.
96. Brandes JL, Jacobs D, Neto W, Bhattacharaya S. Topiramate in the prevention of migraine headache: A randomized, double-blind, placebo-controlled, parallel study (MIGR-002). Neurology. 2003;60(Suppl 1):A238. Abstract P03.155.
97. Rothrock JF, Jacobs D, Neto W Bhattacharaya S. Safety and tolerability of topiramate in migraine prevention: Results from a multicenter, randomized, double-blind, placebo-controlled study (MIGR-002). Neurology. 2003;60(Suppl 1):A238. Abstract P03.156.
98. Krusz JC. Zonisamide in the treatment of headache disorders. Cephalalgia. 2001; 21:374-375. Abstract.
99. Wheeler SD. Lamotrigine efficacy in migraine prevention. Cephalalgia. 2001;21:374. Abstract.
100. Candis MM, Susan GL, Carol PS. Effects of gabapentin compared to amitriptyline on pain in diabetic neuropathy. Diabetes. 1998;47:A374. Abstract.
101. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: An open-label pilot study. J Pain Symptom Manage. 2000;20:280-285.
102. Cheshire WP Jr. Defining the role for gabapentin in the treatment of trigeminal neuralgia: A retrospective study. J Pain. 2002;3:137-142.
103. Samkoff LM, Daras M, Tuchman AJ, Koppel BS. Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin. Neurology. 1997;49:304-305.
104. Solaro C, Uccelli MM, Guglieri P, et al. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler. 2000;6:192-193.
105. Sist TC, Filadora VA II, Miner M, Lema M. Experience with gabapentin for neuropathic pain in the head and neck: Report of ten cases. Reg Anesth. 1997;22:473-478.
106. Lampi C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura - a pilot study. Cephalalgia. 1999;19:58-63.
107. D'Andrea G, Granella F, Ghiotto N, Nappi G. Lamotrigine in the treatment of SUNCT syndrome. Neurology. 2001;57:1723-1725.
108. Leone M, Rigamonti A, Usai S, et al. Two new SUNCT cases responsive to lamotrigine. Cephalalgia. 2000;20:845-847.
109. Lindstrom P. The analgesic effect of carbamazepine in trigeminal neuralgia. Pain. 1987;28(Suppl 4):S85. Abstract.
110. Remillard G. Oxcarbazepine and intractable trigeminal neuralgia. Epilepsia. 1994;35 (Suppl 3):S28-S29. Abstract.
111. Lopez MR, Santiago ER, Ramos RR, Zenteno JS. Symptomatic treatment of trigeminal neuralgia with oxcarbazepine. J Neurol Sci. 1997;150(Suppl 1):S34-S35.
112. Jensen MG, Royal MA, Ward S, et al. An open-label trial of oxcarbazepine in patients with radiculopathy refractory to gabapentin. Pain Clin. 2002:11-14.
113. Bajwa ZH, Sami N, Warfield CA, Wootton J. Topiramate relieves refractory intercostal neuralgia. Neurology. 1999;52:1917.
114. Zvartau-Hind M, Din MU, Gilani A, et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology. 2000;55:1587-1588.
115. Krusz JC. Zonisamide in the treatment of pain and headache disorders. J Neurol Sci. 2001;187(Suppl 1):S107. Abstract.
116. Kaplan M. Zonisamide - Benefits in chronic pain patients. Arch Phys Med Rehabil. 2002;83:1671. Abstract.
117. Royal M, Jensen M, Gunyea I, et al. Retrospective case series of zonisamide in the treatment of neuropathic pain. Poster presented at: Annual Meeting of the American Epilepsy Society; November 30-December 5, 2001; Philadelphia, Pa.
118. Cochran JW. Efficacy of zonisamide in the treatment of neuropathic pain. J Pain. 2002;3(Suppl 1):39. Abstract 752.
119. Bernstein CD, Diaz JH, Gould HJ. A possible role for zonisamide in treating neuropathic pain: A case of idiopathic polyneuropathy. Pain Pract. 2002;2:134-136.
120. Wallace MS. Zonisamide for complex regional pain syndrome. J Pain. 2002;3(Suppl 1):42. Abstract.
121. Drake ME, Greathouse NI, Armenthright AD, Renner JB. Zonisamide in the prophylaxis of migraine headache. Cephalalgia. 2001;21:374. Abstract.
122. Cochran JW Efficacy of zonisamide in prophylactic treatment of migraine headaches with or without aura: Open-label experience in 7 patients. J Pain. 2002;3(Suppl 1):39. Abstract.
123. Smith TR. Treatment of refractory chronic daily headache with zonisamide: A case series. Poster presentedat: Annual Meeting of the American Epilepsy Society; November 30-December 5, 2001; Philadelphia, Pa.
124. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: A systematic review of their efficacy and tolerability. Epilepsia. 1997;38:859-880.
125. Ferrendelli JA. Concerns with antiepileptic drug initiation: Safety, tolerability, and efficacy. Epilepsia. 2001;42(Suppl 4):28-30.
126. Physicians' Desk Reference. 56th ed. Montvale, NJ: Medical Economics Company; 2002:1559.
127. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother. 1999;33:1037-1042.
128. Calabrese JR, Bowden CL, Sachs GS, et al, for the Lamictal 602 Study Group. A double blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999;60:79-88.
129. Leppik IE. Three new drugs for epilepsy: Levetiracetam, oxcarbazepine, and zonisamide. J Child Neurol 2002;17(Suppl 1):S53-S57.
130. Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res. 2003;11:556-562.
131. Ritter FJ, Gustafson MC, Karney V, Penovich PE. Do allergic reactions to sulfonamide antibiotics predict allergy to zonisamide? Poster presented at: Annual Meeting of the American Epilepsy Society; November 30-December 5, 2001; Philadelphia, Pa.
132. Welty TE, Kuzniecky RI, Limdi N, Faught E. Weight loss associated with use of zonisamide in European and US clinical trials. Poster presented at: American Epilepsy Society Annual Meeting; November 30-December 5, 2001; Philadelphia, Pa.
133. Armijo JA, Adin-Ibarra J, Sanchez-Baglietto N, Vega-Gil N. Monitoring serum levels of new antiepileptics [in Spanish]. Rev Neurol. 2002;35(Suppl 1):S116-S134.
134. Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol. 2000;55:697-705.
135. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet. 2000;38:191-204.
136. Chong E, Dupuis LL. Therapeutic drug monitoring of lamotrigine. Ann Pharmacother. 2002;36:917-920.
137. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: Review on drug interactions. Ther Drug Monit. 2002;24:91-103.
138. Natsch S, Hekster YA, Keyser A, et al. Newer anticonvulsant drugs: Role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf. 1997; 17:228-240.
139. Berry DJ, Besag FM, Pool F, et al. Lack of an effect of topiramate on lamotrigine serum concentrations. Epilepsia. 2002;43:818-823.
140. Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: A review of human studies. Fundam Clin Pharmacol. 2000;14:301-319.
141. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16:263-272.
142. Gatti G, Bonomi I, Jannuzzi G, Perucca E. The new antiepileptic drugs: Pharmacological and clinical aspects. Curr Pharm Des. 2000;6:839-860.
143. Rosenfeld WE. Safety and tolerability of zonisamide used concurrently with topiramate. Poster presented at: Annual Meeting of the American Epilepsy Society; November 30-December 5, 2001; Philadelphia, Pa.
144. Vazquez B, Ghacigeh G, Hopkins M, Devinsky O. Zonisamide and topiramate combination therapy: Safety and tolerability. Epilepsia. 2001;42(Suppl 7):261. Abstract.